See more : Limco Del Mar, Ltd. (LIDM) Income Statement Analysis – Financial Results
Complete financial analysis of Theriva Biologics, Inc. (TOVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theriva Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ganesha Ecosphere Limited (GANECOS.BO) Income Statement Analysis – Financial Results
- QuakeSafe Technologies Co., Ltd. (300767.SZ) Income Statement Analysis – Financial Results
- Nikhil Adhesives Limited (NIKHILAD.BO) Income Statement Analysis – Financial Results
- SmartFinancial, Inc. (SMBK) Income Statement Analysis – Financial Results
- Terax Energy, Inc. (TEXG) Income Statement Analysis – Financial Results
Theriva Biologics, Inc. (TOVX)
About Theriva Biologics, Inc.
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.16M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 506.57K | 399.38K | 400.00K | 500.00K | 500.00K | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 467.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 118.78K | 86.34K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 100.00K |
| Gross Profit | -135.00K | -268.00K | -87.00K | -201.00K | -240.00K | -272.00K | -245.00K | -157.00K | -72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 2.70M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 387.80K | 313.04K | 300.00K | 400.00K | 400.00K | 100.00K | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.22% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 76.55% | 78.38% | 75.00% | 80.00% | 80.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 14.31M | 11.72M | 7.80M | 5.13M | 11.08M | 11.84M | 18.78M | 29.11M | 32.91M | 14.49M | 6.51M | 12.29M | 3.34M | 1.58M | 1.20M | 4.64M | 6.33M | 2.67M | 946.07K | 3.62M | 6.00M | 3.75M | 3.42M | 2.40M | 5.40M | 0.00 | 4.40M | 0.00 | 0.00 |
| General & Administrative | 7.16M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.07M | 5.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 624.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 763.00K | 5.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.78M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.83M | 5.01M | 2.59M | 2.70M | 2.58M | 2.68M | 3.81M | 1.44M | 285.70K | 4.48M | 4.55M | 2.82M | 2.28M | 3.00M | 4.60M | 7.70M | 3.00M | 6.40M | 3.60M |
| Other Expenses | -660.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.28M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.68M | 5.79M | 5.50M | 10.10M | 7.80M | 7.40M | 6.40M | 3.70M |
| Cost & Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.75M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.80M | 5.87M | 5.60M | 10.20M | 7.90M | 7.40M | 6.40M | 3.80M |
| Interest Income | 1.44M | 512.00K | 6.00K | 44.00K | 283.00K | 67.00K | 21.00K | 37.00K | 6.00K | 3.00K | 33.00K | 33.00K | 14.00K | 413.00 | 2.97K | 128.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.11K | 9.88K | 13.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 20.00K | 43.00K | 63.00K | 201.00K | 358.71K | 382.09K | 404.62K | 199.63K | 30.68K | 2.26K | -154.13K | -130.55K | -118.78K | -86.34K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | -100.00K |
| EBITDA | -19.85M | -21.58M | -14.19M | -9.96M | -15.42M | -17.30M | -26.01M | -39.10M | -40.91M | -20.48M | -11.53M | -17.22M | -7.48M | -1.22M | -3.34M | -6.91M | -9.94M | -4.07M | -1.28M | -8.09M | -9.76M | -6.42M | -5.39M | -5.15M | -7.90M | -7.40M | -7.30M | -6.30M | -3.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38.71% | -3,158.80% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,116.24% | -1,266.71% | 2,407.29% | 2,025.00% | -1,940.00% | -1,480.00% | -7,300.00% | -6,400.00% | -3,500.00% |
| Operating Income | -21.43M | -21.58M | -14.27M | -10.16M | -15.66M | -17.57M | -26.25M | -39.25M | -40.98M | -20.50M | -12.34M | -17.30M | -5.93M | -1.58M | -3.68M | -7.32M | -10.14M | -4.12M | -1.36M | -8.09M | -9.68M | -6.30M | 9.70M | 8.20M | -9.60M | -7.30M | -7.30M | -6.40M | -3.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -50.05% | -3,571.17% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,107.12% | -1,243.26% | 2,428.90% | 2,050.00% | -1,920.00% | -1,460.00% | -7,300.00% | -6,400.00% | -3,400.00% |
| Total Other Income/Expenses | 1.44M | 471.00K | 6.00K | 44.00K | 283.00K | 4.15M | 10.76M | 11.45M | -3.81M | 718.00K | 21.00K | 15.00K | -1.70M | -127.21K | -43.01K | -357.00 | 245.88K | -12.50K | 1.34M | 0.00 | 79.71K | 237.55K | 172.68K | 250.00K | -1.50M | 100.00K | 7.30M | 0.00 | 200.00K |
| Income Before Tax | -19.99M | -21.11M | -14.27M | -10.12M | -15.38M | -13.42M | -15.49M | -27.80M | -44.79M | -19.78M | -12.32M | -17.28M | -7.63M | -1.71M | -3.72M | -7.32M | 0.00 | -4.13M | -1.39M | 0.00 | -9.60M | -6.06M | -5.30M | -5.00M | -9.50M | -7.20M | 0.00 | -6.30M | -3.50M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,612.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.00% | -1,195.96% | -1,326.94% | -1,250.00% | -1,900.00% | -1,440.00% | 0.00% | -6,300.00% | -3,500.00% |
| Income Tax Expense | -1.64M | -1.43M | -94.00K | -117.00K | -360.00K | -4.20M | -11.08M | -12.00M | 2.76M | -718.00K | -22.00K | -231.00K | 2.22M | 10.11K | 49.93K | -114.05K | -245.88K | -5.48K | 36.63K | 677.06K | -67.57K | -295.25K | 12.09M | 13.60M | 0.00 | -200.00K | 7.40M | 0.00 | 400.00K |
| Net Income | -18.35M | -19.69M | -14.17M | -10.00M | -15.02M | -13.37M | -15.17M | -27.26M | -43.74M | -19.78M | -12.32M | -17.07M | -8.15M | -1.71M | -3.73M | -7.21M | -9.89M | -4.10M | -1.36M | -8.62M | -9.48M | -5.76M | -17.38M | -18.60M | -9.50M | -7.00M | -7.40M | -6.30M | -3.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,619.60% | 0.00% | 0.00% | 0.00% | 0.00% | -86,175.82% | -1,084.45% | -1,137.68% | -4,352.97% | -4,650.00% | -1,900.00% | -1,400.00% | -7,400.00% | -6,300.00% | -3,900.00% |
| EPS | -28.49 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -28.48 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 644.00K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 644.28K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
– Initiated dosing at U.S. sites for VIRAGE – – Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated – – VIRAGE remains on track to complete enrollment in the first quarter of 2024 –
Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results
ROCKVILLE, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a...
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatment
Theriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic...
Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results
ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a...
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Conference call to be held on Thursday, March 30 at 8:30 a.m. ET
Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a...
Theriva Biologics to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's...
Theriva Biologics (TOVX) Q3 2022 Earnings Call Transcript
Theriva Biologics (NYSE:TOVX ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive and Chief Financial Officer Manel Cascalló - General Director, Theriva Biologics Europe Frank...
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
-Conference call to be held on Friday, November 11 at 8:30 a.m. ET-
Source: https://incomestatements.info
Category: Stock Reports